A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

The anti-HER2 antibody trastuzumab have shown clinical activity in combination with chemotherapy in different breast cancer settings. However, most of patients treated with this antibody progress after a period of treatment. Activation of the kinase SRC has been linked with resistance to trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocana, Alberto, Gil-Martin, Marta, Martín, Miguel, Rojo, Federico, Antolín, Silvia, Guerrero, Ángel, Trigo, José Manuel, Muñoz, Montse, Pandiella, Atanasio, Diego, Núria Gonzalo, Bezares, Susana, Caballero, Rosalía, Carrasco, Eva, Urruticoechea, Ander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641200/
https://www.ncbi.nlm.nih.gov/pubmed/29069857
http://dx.doi.org/10.18632/oncotarget.17113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641200/
https://www.ncbi.nlm.nih.gov/pubmed/29069857
http://dx.doi.org/10.18632/oncotarget.17113

Ejemplares similares